FEROX STRATEGIES

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 3

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.